Home
|
Inbox
|
Search
|
View Abstract
Adherence to Therapy and Patient Reported Satisfaction Using a Novel Airway Clearance and Lung Expansion Treatment in Motor Neuron Disease (MND) and Cystic Fibrosis (CF) Patients in the Home Setting
Description
.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px } .abstract { overflow-x:scroll } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px } .abstract td, th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; } .abstract a { overflow-wrap: break-word; word-wrap: break-word; }
A6271 - Adherence to Therapy and Patient Reported Satisfaction Using a Novel Airway Clearance and Lung Expansion Treatment in Motor Neuron Disease (MND) and Cystic Fibrosis (CF) Patients in the Home Setting
Author Block: R. Sharma, M. Prickett, J. M. Coleman, J. L. Hixon, L. F. Wolfe; Division of Pulmonary and Critical Care Medicine, Northwestern University, Chicago, IL, United States.
RATIONALE: Airway clearance therapy is a key component of care for many patients, including those with CF and neuromuscular disorders such as MND. Patients with CF suffer hyperproduction of thick pulmonary secretions. MND patients have low lung volumes and a weak cough. Both groups are at risk for pulmonary complications. Airway clearance, hyperinflation, and cough assistance therapies are commonly used to avoid respiratory infection.
The MN4000 is a home version of The MetaNeb® System, a novel therapy device which provides continuous high-frequency oscillation (CHFO) and continuous positive expiratory pressure (CPEP) for airway clearance and lung expansion. The purpose of this study is to provide preliminary feasibility and effectiveness data for this therapy in the home setting.
METHODS: This is a non-randomized open-label pilot study. All enrolled subjects received treatment with the MN4000. Treatment settings were adjusted to patient comfort and tolerance. Subjects were seen for baseline visits, after 30 days and after approximately 90 days of therapy. Adherence was self-reported using an on-line tool. Treatment satisfaction surveys were administered at baseline, 30-day and 90-day visits. Lung function was assessed at baseline and follow-up visits.
RESULTS: 5 stable CF subjects and 5 stable MND subjects were enrolled. All completed the 30-day and 9 patients completed the 90-day follow-up. Most patients were prescribed minimum twice-daily 10-minute therapy. Mean reported adherence to prescribed therapy was 97% in the CF group and 95% in the MND group. Satisfaction scores were positive, all subjects reported therapy as ""easy to use"". 5 of 9 subjects rated therapy ""more effective"" and 2 subjects rated therapy ""equally effective"" as current therapy. 9 of 10 subjects stated therapy helpful in maintaining lung health. Subjects reported seldom missing therapy.
Spirometry measures remained stable. Percent predicted FEV1 results at baseline and after 90 days were 64 + 19 vs. 67 + 22 for CF subjects (n=4) and 59 + 19 vs. 59 + 28 for MND subjects (n=5). Percent predicted FVC results at baseline and 90 days for CF subjects were 74 + 21 vs. 75 + 23. Percent predicted SVC results for MND subjects at baseline and 90 days were 55 + 14 vs. 55 + 27.
CONCLUSIONS: In this short-term study, patients found MN4000 therapy easy to use and reported high adherence. Our data suggest CHFO and CPEP therapy may have a novel role in the outpatient treatment of patients with CF and MND.
Author Block: R. Sharma, M. Prickett, J. M. Coleman, J. L. Hixon, L. F. Wolfe; Division of Pulmonary and Critical Care Medicine, Northwestern University, Chicago, IL, United States.
RATIONALE: Airway clearance therapy is a key component of care for many patients, including those with CF and neuromuscular disorders such as MND. Patients with CF suffer hyperproduction of thick pulmonary secretions. MND patients have low lung volumes and a weak cough. Both groups are at risk for pulmonary complications. Airway clearance, hyperinflation, and cough assistance therapies are commonly used to avoid respiratory infection.
The MN4000 is a home version of The MetaNeb® System, a novel therapy device which provides continuous high-frequency oscillation (CHFO) and continuous positive expiratory pressure (CPEP) for airway clearance and lung expansion. The purpose of this study is to provide preliminary feasibility and effectiveness data for this therapy in the home setting.
METHODS: This is a non-randomized open-label pilot study. All enrolled subjects received treatment with the MN4000. Treatment settings were adjusted to patient comfort and tolerance. Subjects were seen for baseline visits, after 30 days and after approximately 90 days of therapy. Adherence was self-reported using an on-line tool. Treatment satisfaction surveys were administered at baseline, 30-day and 90-day visits. Lung function was assessed at baseline and follow-up visits.
RESULTS: 5 stable CF subjects and 5 stable MND subjects were enrolled. All completed the 30-day and 9 patients completed the 90-day follow-up. Most patients were prescribed minimum twice-daily 10-minute therapy. Mean reported adherence to prescribed therapy was 97% in the CF group and 95% in the MND group. Satisfaction scores were positive, all subjects reported therapy as ""easy to use"". 5 of 9 subjects rated therapy ""more effective"" and 2 subjects rated therapy ""equally effective"" as current therapy. 9 of 10 subjects stated therapy helpful in maintaining lung health. Subjects reported seldom missing therapy.
Spirometry measures remained stable. Percent predicted FEV1 results at baseline and after 90 days were 64 + 19 vs. 67 + 22 for CF subjects (n=4) and 59 + 19 vs. 59 + 28 for MND subjects (n=5). Percent predicted FVC results at baseline and 90 days for CF subjects were 74 + 21 vs. 75 + 23. Percent predicted SVC results for MND subjects at baseline and 90 days were 55 + 14 vs. 55 + 27.
CONCLUSIONS: In this short-term study, patients found MN4000 therapy easy to use and reported high adherence. Our data suggest CHFO and CPEP therapy may have a novel role in the outpatient treatment of patients with CF and MND.
|
Home
|
Inbox
|
Search
|